Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Study in low-risk patients reveals 5-year survival rate of 93%

News | Cardiovascular Surgery

Largest US Cardiac Database Shows Excellent Long-term Survival After Surgical Aortic Valve Replacement

October 18, 2023 — A study published in The Annals of Thoracic Surgery demonstrates outstanding long-term survival ...

October 18, 2023

News | Cardiovascular Surgery

Walgreens and the Cardiovascular Research Foundation Unite to Improve Recognition and Diagnosis of Valvular Heart Disease for Older Americans

October 18, 2023 — Walgreens and the Cardiovascular Research Foundation (CRF) announced a collaboration to drive forward ...

October 18, 2023

Initial data indicate that DSR 2.0 is safe and well tolerated, restores diuretic response and improves cardiorenal status

News | Heart Failure

Sequana Medical Announces Initial Positive Data from MOJAVE, a US Phase 1/2a Study of DSR 2.0 for Treatment of Heart Failure Through Breaking Vicious Cycle of Cardiorenal Syndrome

October 18, 2023 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

October 18, 2023

University of Cincinnati to partner with UNC, Duke for large prospective study

News | Stroke

Learning More About How Cancer Affects Stroke Risk

October 17, 2023 — Patients with a previous or current cancer diagnosis are more likely to have a stroke than the ...

October 17, 2023

Scientists from The Florey are among the world’s leading stroke experts who have mapped out how researchers and clinicians can improve outcomes for people who have survived a stroke.

News | Stroke

International Experts Push for Innovation to Improve Stroke Recovery

October 17, 2023 — Scientists from The Florey are among the world’s leading stroke experts who have mapped out how ...

October 17, 2023

Novel platform for structural heart interventions now in human use, with ability to improve patient recovery and reduce anesthesia and hospital stays

News | Cardiovascular Clinical Studies

BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II

October 12, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

October 12, 2023

Combination of Tenaya’s HDAC6 inhibitors with Empagliflozin Shows Additive Benefits in Preclinical HFpEF Model and Highlights Differentiated Mechanism of Action

News | Heart Failure

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

October 11, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

October 11, 2023

Feature | Cardiovascular Clinical Studies | Christine Book

“One on One” with Christine Seidman, MD, FACC, on Hypertrophic Cardiomyopathy

October 11, 2023 — To gain the latest insight into genetic research for the treatment of hypertrophic cardiomyopathy ...

October 10, 2023

REBALANCE-HF early feasibility trial met objective of identifying responder group with demonstrated benefits in heart function, hemodynamics, and physical activity at 6 months

News

Late-Breaking Data Confirms Safety of Axon Therapies' Innovative Heart Failure Procedure and Identifies Patients Most Likely to Benefit from SAVM Therapy

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

October 10, 2023

The study marks a new standard for inclusive medicine with recruitment for target demographics reaching over 3x the national average

News | Cardiovascular Clinical Studies

Hawthorne Effect Announces Monumental Diversity in Patient Recruitment Data for Valvular Heart Disease Study

October 10, 2023 — Hawthorne Effect, a complete clinical trials solution, announced interim recruitment results for the ...

October 10, 2023

Primary endpoint, six-month clinical and imaging data from clinical trial of DESyne BDS Plus stent system evaluating safety and efficacy of localized delivery of anticoagulants and an anti-proliferative agent designed to reduce the implant thrombotic risk

News | Stents Drug Eluting

Elixir Medical To Present Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

October 10, 2023

The program is recommended by the Centers for Medicare and Medicaid services for patients who undergo heart valve repair or replacement

News | Heart Failure

TAVR: Less Than One-third of Patients Enter Cardiac Rehab After Heart Procedure

October 9, 2023 — The vast majority of people who have a minimally invasive heart valve replacement procedure do not ...

October 09, 2023

Rejuvenate Bio announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key disease-mediating pathways. RJB-0402 demonstrated efficacy in a mouse model of arrhythmogenic cardiomyopathy (ACM)

News | Sudden Cardiac Arrest

Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy

October 9, 2023 — Rejuvenate Bio announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key ...

October 09, 2023

Endotronix announced FDA approval for the PROACTIVE-HF 2 IDE trial with the Cordella Sensor to expand market access and shared positive results from a substudy of their pivotal PROACTIVE-HF clinical trial. The company plans to share full results from the PROACTIVE-HF trial next year.

News | Cardiovascular Clinical Studies

Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial

October 9, 2023 — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment ...

October 09, 2023

$Retrospective study of over 18,000 drug-refractory AFib patients found those treated with catheter ablation had a 57% lower risk of developing heart failure compared to those receiving antiarrhythmic drugs$